A composite gel containing platelet-rich plasma and ethylphenolsulfonamide and preparation method thereof

Abstract

The invention discloses a composite gel containing platelet-rich plasma and ethylphenolsulfonamide, wherein the raw materials for preparing the composite gel include hydroxypropyl chitosan, double-terminated benzaldehyde-polyethylene glycol, platelet-rich plasma and ethylphenolsulfonamide, and the mass fractions of the four components are 1%-10%, 3%-25%, 2%-10%, and 1%-10%, respectively. The composite gel of the invention realizes the combined application of platelet-rich plasma and ethylphenolsulfonamide, and at the same time delays the release rate of platelet-rich plasma and ethylphenolsulfonamide, prolongs the drug effect, and thus more effectively treats body trauma.

Description

Technical Field

[0001] The invention belongs to the technical field of medical polymer materials, and in particular relates to a composite gel containing platelet-rich plasma and ethylphenolsulfonamide and a preparation method thereof. Background Art

[0002] Fatal massive bleeding is the main cause of casualties in combat and the deaths of wounded soldiers in traumatic events such as car accidents and surgeries. Infection is another major cause of death after blood loss. Therefore, timely and effective treatment of wounds to stop bleeding and prevent bacterial infection, as well as promoting wound healing to a certain extent, plays a decisive role in improving the efficiency of treatment and later recovery of wounded soldiers.

[0003] Chitosan can achieve the purpose of hemostasis by promoting the aggregation of red blood cells and platelets, but single-component chitosan is almost insoluble in water, which limits its development and utilization to a certain extent. Modification treatment is needed to break through the limitations of chitosan.

[0004] Polyethylene glycol (PEG) is a non-toxic, non-immunogenic, non-irritating polymer that is soluble in water and a variety of organic components. It is approved by the FDA as a polymer material that can be used in living organisms. It is widely used in medicine and cosmetics fields such as drug sustained release, surface modification of medical polymer materials, and cosmetic moisturizers.

[0005] Platelet-rich plasma (PRP) is a highly concentrated form of platelets that is also rich in fibrinogen and various growth-promoting factors. It is commonly used in surgical hemostasis, burn healing, plastic surgery, sports medicine, and other fields. Lyophilized Platelet-rich plasma (LPRP) prepared by freeze-drying technology can not only maintain its original biological properties, but also has low requirements for the storage environment and can extend the storage time.

[0006] Ethamidine accelerates coagulation by enhancing platelet aggregation and adhesion and promoting the release of coagulation substances.

[0007] At present, there is no report on adding platelet-rich plasma and ethylphenolsulfonamide to the same carrier at the same time so that the two drugs can exert their efficacy at the same time. Summary of the invention

[0008] In order to achieve the combined use of platelet-rich plasma and ethylphenolsulfonamide, the release rate of platelet-rich plasma and ethylphenolsulfonamide is slowed down, the efficacy is prolonged, and the body trauma is treated more effectively.

[0009] In the first aspect, the present invention provides a composite gel containing platelet-rich plasma and ethylphenolsulfonamide, which is prepared from raw materials including hydroxypropyl chitosan, double-terminated benzaldehyde-polyethylene glycol, platelet-rich plasma and ethylphenolsulfonamide. The mass fraction of the hydroxypropyl chitosan is 1%-10%, the mass fraction of the double-terminated benzaldehyde-polyethylene glycol is 3%-25%, the mass fraction of the platelet-rich plasma is 2%-10%, and the mass fraction of the ethylphenolsulfonamide is 1%-10%.

[0010] Preferably, the mass fraction of hydroxypropyl chitosan is 1%-7%, more preferably 1%-4%, for example: 1%, 1.2%, 1.4%, 1.5%, 1.7%, 2.0%, 2.1%, 2.2%, 2.3%, 2.5%, 2.7%, 3.0%, 3.2%, 3.4%, 3.5%, 3.7%, 4.0%.

[0011] Preferably, the mass fraction of the double-terminated benzaldehyde-polyethylene glycol is 3%-20%, more preferably 4%-20%, for example: 4.0%, 4.2%, 4.5%, 4.7%, 5.0%, 5.2%, 5.5%, 5.7%, 6.0%, 6.3%, 6.6%, 7.0%, 7.3%, 7.7%, 8.0%, 8.4%, 8.8%, 9.1 %, 9.5%, 10.0%, 10.5%, 11.0%, 11.6%, 12.0%, 12.4%, 13.0%, 13.5%, 14.0%, 14.6%, 15.0%, 15.5%, 16.0%, 16.6%, 17.1%, 17.7%, 18.2%, 18.7%, 19.3%, 19.6%, 20.0%.

[0012] Preferably, the mass fraction of the platelet-rich medium is 2%-6%, more preferably 3.5%-6%, for example: 3.5%, 3.8%, 4.0%, 4.3%, 4.8%, 5.0%, 5.5%, 6.0%.

[0013] Preferably, the mass fraction of ethylphenolsulfonamide is 1.5%-5%, more preferably 1.5%-4%, for example: 1.5%, 1.9%, 2.3%, 2.7%, 3.0%, 3.3%, 3.6%, 4.0%.

[0014] Preferably, the mass ratio of the hydroxypropyl chitosan to the double-terminated benzaldehyde-polyethylene glycol is 1:3-10, and more preferably 1:3-8, for example: 1:3, 1:3.3, 1:3.7, 1:4, 1:4.3, 1:4.7, 1:5, 1:5.3, 1:5.7, 1:6, 1:6.3, 1:6.7, 1:7, 1:7.3, 1:7.7, 1:8.

[0015] Preferably, the mass ratio of the hydroxypropyl chitosan to the platelet-rich plasma is 1:2-6, more preferably 1:2-4, for example: 1:2, 1:2.4, 1:2.7, 1:3, 1:3.4, 1:3.7, 1:4.0.

[0016] Preferably, the mass ratio of the hydroxypropyl chitosan to the ethylamine is 1:1-4, more preferably 1:1-2.5, for example: 1:1.0, 1:1.1, 1:1.2, 1:1.3, 1:1.4, 1:1.5, 1:1.6, 1:1.7, 1:1.8, 1:1.9, 1:2.0, 1:2.1, 1:2.2, 1:2.3, 1:2.4, 1:2.5.

[0017] Preferably, the platelet-rich plasma is freeze-dried platelet-rich plasma.

[0018] In the second aspect, the present invention provides a method for preparing the composite gel described in the first aspect. The inventor utilizes the principle of Schiff base reaction to react hydroxypropyl chitosan and double-terminated benzaldehyde-polyethylene glycol to obtain a polymer drug carrier matrix, and then combines platelet-rich plasma and ethylphenolsulfonamide with the drug-carrying matrix to obtain the composite gel described in the first aspect.

[0019] In a specific embodiment of the present invention, the preparation method specifically comprises the following steps:

[0020] preparing a hydroxypropyl chitosan solution and a double-terminated benzaldehyde-polyethylene glycol solution;

[0021] Adding platelet-rich plasma and ethylphenolsulfonamide to the double-terminated benzaldehyde-polyethylene glycol solution respectively, and mixing them evenly to obtain a mixed solution A;

[0022] The mixed solution A is added dropwise into the hydroxypropyl chitosan solution, stirred evenly, and allowed to stand to obtain the composite gel.

[0023] Preferably, the mass fraction of the hydroxypropyl chitosan solution is 2%-10%, more preferably 3%-8%, for example: 3.0%, 3.5%, 4.0%, 4.5%, 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%.

[0024] Preferably, the solvent of the hydroxypropyl chitosan solution is at least one of phosphate buffer solution (PBS), distilled water and purified water, and more preferably is PBS solution.

[0025] Preferably, the molecular weight of the hydroxypropyl chitosan is 1000Da-4000 Da, more preferably 1500Da-4000 Da, more preferably 1500Da-3000 Da, for example: 1500Da, 1800Da, 2000Da, 2300Da, 2500Da, 2800Da, 3000Da.

[0026] Preferably, the mass fraction of the double-ended benzaldehyde-polyethylene glycol solution is 5%-50%, and more preferably 10%-45%, for example: 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%, 27.5%, 30%, 32.5%, 35%, 37.5%, 40%, 42.5%, 45%.

[0027] Preferably, the solvent of the double-terminated benzaldehyde-polyethylene glycol solution is at least one of phosphate buffer solution (PBS), distilled water and purified water, and more preferably is PBS solution.

[0028] Preferably, in the mixed solution A, the mass fraction of the platelet-rich plasma is 5%-20%, more preferably 5%-15%, for example: 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%.

[0029] Preferably, the platelet-rich plasma is freeze-dried platelet-rich plasma.

[0030] Preferably, in the mixed solution A, the mass fraction of ethylphenolsulfonamide is 2%-10%, more preferably 3%-7%, for example: 3.0%, 3.3%, 3.6%, 4.0%, 4.3%, 4.7%, 5.0%, 5.3%, 5.7%, 6.0%, 6.3%, 6.7%, 7.0%.

[0031] In a third aspect, the present invention provides application of the preparation method described in the second invention in the preparation of medical dressings.

[0032] Preferably, the medical dressing comprises a spray, drops or a patch, such as a liquid band-aid or a traditional band-aid.

[0033] In a fourth aspect, the present invention provides a medical dressing, the raw materials for preparing the medical dressing include the composite gel described in the first aspect.

[0034] Preferably, the medical dressing comprises a spray, drops or a patch, such as a liquid band-aid or a traditional band-aid.

[0035] Beneficial effects of the present invention:

[0036] The invention prepares hydroxypropyl chitosan and double-terminated benzaldehyde-polyethylene glycol into a drug carrier matrix, and adds platelet-rich plasma and ethylphenolsulfonamide, so that the platelet-rich plasma and ethylphenolsulfonamide can simultaneously exert drug effects, and can more effectively promote the repair and healing of body wounds; in addition, the drug carrier matrix can control the sustained release of the drug, prolong the action time of the drug, and improve the drug efficacy. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 The effect of scanning frequency on the modulus of composite gel in the mechanical test of the present invention;

[0038] Figure 2 The effect of strain on the modulus of the composite gel in the mechanics of the present invention;

[0039] Figure 3 Dynamic rheological analysis of the composite gel of the present invention;

[0040] Figure 4 This is the electron microscope scanning result of the composite gel of the present invention;

[0041] Figure 5 This is the Fourier infrared spectrum of the composite gel of the present invention;

[0042] Figure 6 The hemostatic effect of the composite gel of the present invention;

[0043] Figure 7 The antibacterial effect of the composite gel of the present invention;

[0044] Figure 8 The composite gel of the present invention promotes the wound healing effect. DETAILED DESCRIPTION

[0045] The present invention will be further described below in conjunction with specific embodiments and accompanying drawings, and the advantages and features of the present invention will become clearer as the description proceeds. However, these embodiments are merely exemplary and do not constitute any limitation to the scope of the present invention. It should be understood by those skilled in the art that the details and forms of the technical solution of the present invention may be modified or replaced without departing from the spirit and scope of the present invention, but these modifications and replacements all fall within the scope of protection of the present invention.

[0046] Example 1 Preparation of composite gel sample

[0047] 1. Preparation of composite gel sample 1

[0048] 1.1 Weigh the materials according to the ratio in Table 1.

[0049] Table 1: Material ratio

[0050]

[0051] 1.2 Preparation of composite gel

[0052] The specific preparation process of composite gel sample 1 includes:

[0053] 1) Weigh 0.5 g of hydroxypropyl chitosan with a molecular weight of 2000 Da, add it to 9.5 mL of PBS solution, and stir until it is completely dissolved to obtain a 5% hydroxypropyl chitosan solution.

[0054] 2) Weigh 2 g of double-terminated benzaldehyde-polyethylene glycol, add it to 8 mL of PBS solution, and stir until it is completely dissolved to obtain a 20% double-terminated benzaldehyde-polyethylene glycol solution.

[0055] 3) Add 1.2 g of freeze-dried platelet-rich plasma and 0.8 g of ethylphenolsulfonamide to the above 20% double-terminated benzaldehyde-polyethylene glycol solution, mix evenly, and stir until completely dissolved to obtain a mixed solution A.

[0056] 4) Under stirring conditions, the mixed solution A prepared in step 3) was added dropwise to the 5% hydroxypropyl chitosan solution prepared in step 1), and the mixture was allowed to stand at room temperature for 5-10 minutes to obtain a composite gel sample 1.

[0057] 2. Preparation of composite gel sample 2

[0058] 2.1 Weigh the materials according to the ratio in Table 2.

[0059] Table 2: Material ratio

[0060]

[0061]

[0062] 2.2 Preparation of composite gel

[0063] The specific preparation process of composite gel sample 2 includes:

[0064] 1) Weigh 0.3 g of hydroxypropyl chitosan with a molecular weight of 1500 Da, add it to 9.7 mL of PBS solution, and stir until it is completely dissolved to obtain a 3% hydroxypropyl chitosan solution.

[0065] 2) Weigh 1 g of double-terminated benzaldehyde-polyethylene glycol, add it to 9 mL of PBS solution, and stir until it is completely dissolved to obtain a 10% double-terminated benzaldehyde-polyethylene glycol solution.

[0066] 3) Add 0.8 g of freeze-dried platelet-rich plasma and 0.4 g of ethylphenolsulfonamide to the above 10% double-terminated benzaldehyde-polyethylene glycol solution, mix evenly, and stir until completely dissolved to obtain a mixed solution A.

[0067] 4) Under stirring conditions, the mixed solution A prepared in step 3) was added dropwise to the 3% hydroxypropyl chitosan solution prepared in step 1, and the mixture was allowed to stand at room temperature for 5-10 minutes to obtain a composite gel sample 2.

[0068] 3. Preparation of composite gel sample 3

[0069] 3.1 Weigh the materials according to the ratio in Table 3.

[0070] Table 3: Material ratio

[0071]

[0072] 3.2 Preparation of composite gel

[0073] The specific preparation process of composite gel sample 3 includes:

[0074] 1) Weigh 0.6 g of hydroxypropyl chitosan with a molecular weight of 3000 Da, add it to 9.4 mL of PBS solution, and stir until it is completely dissolved to obtain a 6% hydroxypropyl chitosan solution.

[0075] 2) Weigh 4 g of double-terminated benzaldehyde-polyethylene glycol, add it to 6 mL of PBS solution, and stir until it is completely dissolved to obtain a 40% double-terminated benzaldehyde-polyethylene glycol solution.

[0076] 3) Add 1.2 g of freeze-dried platelet-rich plasma and 0.8 g of ethylphenolsulfonamide to the above 40% double-terminated benzaldehyde-polyethylene glycol solution, mix evenly, and stir until completely dissolved to obtain a mixed solution A.

[0077] 4) Under stirring, the mixed solution A prepared in step 3) was added dropwise to the 6% hydroxypropyl chitosan solution prepared in step 1), and the mixture was allowed to stand at room temperature for 5-10 minutes to obtain a composite gel sample 3.

[0078] Example 2 Preparation of composite gel comparison sample

[0079] 1. Preparation of composite gel comparison sample 1

[0080] The preparation process of composite gel comparison sample 1 is the same as the preparation process of composite gel sample 1, except that the ingredient list does not contain platelet-rich plasma, and platelet-rich plasma is not added to mixed solution A.

[0081] 2. Preparation of composite gel comparison sample 2

[0082] The preparation process of composite gel comparison sample 1 is the same as the preparation process of composite gel sample 1, except that ethylphenolsulfonamide is not included in the ingredient list, and ethylphenolsulfonamide is not added to the mixed solution A.

[0083] Example 3 Performance test of composite gel sample

[0084] Taking composite gel sample 1 as an example, the prepared composite gel sample was subjected to a performance test, and the specific test process is as follows:

[0085] 1. Mechanical properties test of composite gel sample 1

[0086] 1.1. Under the steady-state conditions of 37°C and 1% shear stress, the composite gel sample 1 was scanned at different frequencies using a rheometer (AR G2, fixture 40 mm) to test the elastic modulus (G′) and viscous modulus (G″) of the composite gel sample. The results are shown in Tables 4 and Figure 1 .

[0087] Table 4 Elastic modulus and viscous modulus at different frequencies

[0088]

[0089] From Table 4 and Figure 1 It can be seen that as the shear frequency increases, G′ fluctuates between 89-115 Pa and G″ fluctuates between 3.6-6 Pa, indicating that the composite gel sample 1 has a relatively constant elastic strength and a certain viscosity.

[0090] 1.2. Under steady-state conditions of 37°C and a shear frequency of 6 rad / s, the elastic modulus (G′) and viscous modulus (G″) of the composite gel sample 1 were measured by changing the strain magnitude using a rheometer (AR G2, fixture 40 mm). The results are shown in Tables 5 and Figure 2 .

[0091] Table 5 Elastic modulus and viscous modulus at different strains

[0092]

[0093]

[0094] From Table 5 and Figure 2 It can be seen that G′ and G″ are relatively constant when the strain is less than 100%. When the strain is greater than 100%, G′ gradually decreases and G″ gradually increases, and the two intersect when the strain is close to 400%. This shows that at 100% strain, composite gel sample 1 has good stability and good elasticity, and then with the increase of strain rate, the elasticity of the composite gel sample gradually increases until the elasticity decreases at 400%, and the fluid properties of composite gel sample 1 have changed.

[0095] 2. Rheological test of composite gel samples

[0096] The elastic modulus (G′) and viscous modulus (G″) of the composite gel samples were measured by a rheometer (ARG2, fixture 40 mm) at 37°C, a shear frequency of 6 rad / s, and dynamic rheology with alternating strains of 1% and 700%. The results are shown in Tables 6 and Figure 3 .

[0097] Table 6 Elastic modulus and viscous modulus at 1% and 700% alternating strains

[0098]

[0099]

[0100] From Table 6 and Figure 3 It can be seen that at low strain (1%), the G′ position of the composite gel sample is around 100Pa, and G″ fluctuates in a small range of 1-46Pa, with the overall G′>G″; when the strain suddenly increases to high strain (700%), the G′ value rapidly decreases to around 20-40Pa, and G″ increases to around 30, and G′≈G″ is the gel state. When high and low strains appear alternately several times, G′ and G″ of MF-CP appear in the same state, indicating that the composite gel sample has the property of self-healing.

[0101] 3. Transmission electron microscopy test of composite gel sample structure

[0102] The microstructure of freeze-dried composite gel sample 1 was observed using a VEGA3 transmission electron microscope. The electron microscope scanning results are shown in Figure 4 .Depend on Figure 4 It can be seen that after the freeze-dried composite gel sample 1 is magnified 100, 200, 500 and 2000 times respectively, the composite gel sample 1 presents a staggered three-dimensional network structure, forming a better spatial structure, so that the hemostatic drug can be loaded into the network.

[0103] 4. Fourier transform infrared spectrometer test of composite gel sample structure

[0104] The microscopic morphology of composite gel sample 1 was scanned using a Fourier transform infrared spectrometer (Thermo Fisher IS5). The Fourier transform infrared spectrometer scanning results are shown in Figure 5 .Depend on Figure 5 It can be seen that the composite gel sample 1 has a medium-wave absorption peak in the vibration region of 1548.14 cm wavelength, and the peak shape is relatively sharp. The absorption peak is in the infrared light vibration region where the Schiff base -C=N- appears, indicating that the composite gel sample 1 has already had a Schiff base reaction.

[0105] Example 4 Hemostatic effect experiment of composite gel sample

[0106] Thirty-two Japanese white rabbits from the same batch were selected and randomly divided into four groups, with eight rabbits in each group. The four experimental groups were: ordinary hemostatic gauze control, composite gel sample group 1, composite gel comparison sample group 1, and composite gel comparison sample group 2. The experimental rabbits were anesthetized and the left ears were depilated. A 0.5 cm long incision was made perpendicular to the artery at 1 / 3 of the auricular artery, and blood gushed out freely. After the blood gushed out freely for 5 seconds, each group of samples was covered on the wound, and a 200g weight was applied to the pressure. The time was immediately counted until the bleeding stopped, the hemostasis time was recorded, and the amount of bleeding was calculated. The results are shown in Tables 7 and Figure 6 .

[0107] Table 7 Hemostasis time and bleeding volume of hemostasis experiment

[0108]

[0109] From Table 7 and Figure 6 It can be seen that compared with the ordinary gauze control, the hemostasis time and bleeding volume of composite gel sample 1, comparative sample 1, and comparative sample 2 were reduced (P < 0.01), and the difference was statistically significant. The hemostasis time of composite gel sample 1, comparative sample 1, and comparative sample 2 were reduced by 44.7%, 23.6%, and 34.6%, respectively, and the bleeding volume was reduced by 85.7%, 53.4%, and 73.0%, respectively.

[0110] In addition, the bleeding time and bleeding volume of composite gel sample 1 were both less than those of composite gel comparison sample 1 and comparison sample 2 (P < 0.05), and the difference was statistically significant. The bleeding time of composite gel sample 1 was reduced by 27.6% and 15.4% compared with composite gel comparison sample 1 and comparison sample 2, respectively, and the bleeding volume was reduced by 69.3% and 47.0% compared with composite gel comparison sample 1 and comparison sample 2, respectively.

[0111] Table 7 and Figure 6 The results show that composite gel sample 1, composite gel comparison sample 1, and composite gel comparison sample 2 all have good hemostatic effects, and can reduce bleeding and prevent excessive blood loss from affecting circulating blood volume. In addition, the hemostatic effect of composite gel sample 1 is better than that of composite gel comparison sample, reflecting the synergistic effect of platelet-rich plasma and ethylphenolsulfonamide.

[0112] Example 5 Antibacterial experiment of composite gel sample

[0113] Take 20 μL of Staphylococcus aureus suspension and evenly spread it on the entire MH agar plate with a sterile coating stick to make a bacterial plate. After sterilizing the tweezers by burning them with an alcohol lamp, stick the blank drug-sensitive paper and the tablets prepared from composite gel sample 1 on the plate respectively. Invert the plate and place it in a 35℃ bacterial incubator for 20 hours. Take it out to observe the antibacterial effect and use a ruler to accurately measure the diameter of the inhibition zone. The results are shown in Table 1. Figure 7.

[0114] from Figure 7 It can be seen that there is no obvious antibacterial zone around the blank tablets; there is an obvious antibacterial zone around the composite gel sample tablets, and the diameter of the antibacterial zone is (18.9±0.6) mm. Figure 7 The results showed that compared with the blank control, the composite gel sample could significantly inhibit Staphylococcus aureus.

[0115] Example 6 Experiment on promoting wound healing with composite gel samples

[0116] Eight Japanese white rabbits from the same batch were selected and randomly divided into two groups, with four rabbits in each group. One group was a control group with ordinary hemostatic gauze, and the other group was a hemostatic gauze group with composite gel sample 1. A circular wound with a diameter of 2 cm was marked on the left side 1 cm away from the center of the rabbit's back spine. A sterile scalpel was used to make a "cross"-shaped full-thickness skin incision at the marked site as a skin scratch model. Immediately after the scratch, two groups of hemostatic gauze were used to cover the scratched area, and the dressing was changed every other day until the 14th day after the injury. The experimental rabbits were killed on the 3rd, 7th and 14th days after the injury to observe the appearance of the wound and take the wound tissue for HE staining to examine the pathological changes in the skin tissue. The results are shown in the figure. Figure 8 .

[0117] from Figure 8 It can be seen that on the third day after the scratch, the wounds of the rabbits in the composite gel sample hemostatic gauze group had some scabs, no obvious necrosis, the outer epidermis of the wound had fallen off, and a small number of inflammatory cells infiltrated; the wounds of the rabbits in the ordinary hemostatic gauze group had exudation, the wounds had not completely formed scabs, and some of them were still exposed to the air, the epidermal cells were necrotic, and there were a large number of inflammatory cells infiltrating. On the seventh day after the scratch, the wounds of the rabbits in the composite gel sample hemostatic gauze group had almost healed, a large number of epidermal cells migrated, a small number of hair follicle cells began to grow, fibroblasts and some new capillaries were visible, and there was almost no inflammatory cell infiltration; the wounds of the rabbits in the ordinary hemostatic gauze group had a large amount of necrosis, and the inflammatory reaction represented by redness and swelling was observed by the naked eye, there were a large number of inflammatory cells infiltrating, and only a small number of epidermal cells migrated. On the 14th day after the scratch, only scars were visible on the wounds of the rabbits in the composite gel sample hemostatic gauze group. The newly generated epidermal cells completely covered the wounds, hair follicle cells had grown out, subcutaneous fibroblast tissue proliferated massively, and the tissue structure was tighter. The wounds of the rabbits in the ordinary hemostatic gauze group had obvious scars, some fibroblasts were generated, but there was still some inflammatory cell infiltration. Figure 8 The results show that, compared with ordinary hemostatic gauze, the composite gel sample of the present invention can better promote wound healing.

[0118] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention is described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A composite gel containing platelet-rich plasma and ethylamine, prepared from raw materials including hydroxypropyl chitosan, double-terminated benzaldehyde-polyethylene glycol, platelet-rich plasma and ethylamine, characterized in that: The mass fraction of the hydroxypropyl chitosan is 1%-10%, the mass fraction of the double-terminal benzaldehyde-polyethylene glycol is 3%-25%, the mass fraction of the platelet-rich plasma is 2%-10%, and the mass fraction of the ethylphenolsulfonamide is 1%-10%.

2. The composite gel according to claim 1, characterized in that: The mass ratio of the hydroxypropyl chitosan to the double-terminated polybenzaldehyde-polyethylene glycol is 1:3-10.

3. The composite gel according to claim 1, characterized in that: The mass ratio of the hydroxypropyl chitosan to the double-terminated polybenzaldehyde-polyethylene glycol is 1:3-8.

4. The composite gel according to claim 1, characterized in that: The mass ratio of the hydroxypropyl chitosan to the platelet-rich plasma is 1:2-6.

5. The composite gel according to claim 1, characterized in that: The mass ratio of the hydroxypropyl chitosan to the platelet-rich plasma is 1:2-4.

6. The composite gel according to claim 1, characterized in that: The mass ratio of the hydroxypropyl chitosan to the ethylphenolsulfonamide is 1:1-4.

7. The composite gel according to claim 1, characterized in that: The mass ratio of the hydroxypropyl chitosan to the ethylphenolsulfonamide is 1:1-2.

5.

8. The composite gel according to any one of claims 1 to 7, characterized in that: The platelet-rich plasma is freeze-dried platelet-rich plasma.

9. A method for preparing a composite gel containing platelet-rich plasma and ethylphenolsulfonamide, characterized in that: The preparation method comprises the following steps: preparing a hydroxypropyl chitosan solution and a double-terminated benzaldehyde-polyethylene glycol solution; The freeze-dried platelet-rich plasma and ethylphenolsulfonamide are added to the double-terminal benzaldehyde-polyethylene glycol solution respectively, and mixed evenly to obtain a mixed solution A; The mixed solution A is added dropwise into the hydroxypropyl chitosan solution, stirred evenly, and allowed to stand to obtain the composite gel.

10. The preparation method according to claim 9, characterized in that: The mass fraction of the hydroxypropyl chitosan solution is 2%-10%; the mass fraction of the double-terminal benzaldehyde-polyethylene glycol solution is 5%-50%.

11. The preparation method according to claim 9, characterized in that: In the mixed solution A, the mass fraction of the platelet-rich plasma is 5%-20%, and the mass fraction of ethylphenolsulfonamide is 2%-10%.

12. Use of the preparation method according to any one of claims 9 to 11 in preparing medical dressings.

13. A medical dressing, characterized in that: The raw material of the medical dressing comprises the composite gel according to any one of claims 1 to 8.

Images